Cited by 231Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume

Open access

Stone, James M., Day, Fern, Tsagaraki, Helen, Valli, Isabel, McLean, Mary A., Lythgoe, David J., O'Gorman, Ruth L., Barker, Gareth J., McGuire, Philip K.·2009·Biological Psychiatry

DOI 10.1016/j.biopsych.2009.05.006

Open this paper in CoChat — free account Open PDF

Abstract

Background The glutamate model of schizophrenia proposes that altered glutamatergic neurotransmission is fundamental to the development of the disorder. In addition, its potential to mediate neurotoxicity raises the possibility that glutamate dysfunction could underlie neuroanatomic changes in schizophrenia. Here we determine whether changes in brain glutamate are present in subjects at ultra high risk of developing psychosis and whether these changes are related to reductions in cortical gray matter volume.Methods Twenty-seven individuals with an at-risk mental state and a group of 27 healthy volunteers underwent proton magnetic resonance spectroscopy and volumetric proton magnetic resonance imaging using a 3-Tesla scanner. Glutamate and glutamine levels were measured in anterior cingulate, left hippocampus, and left thalamus. These measures were then related to cortical gray matter volume.Results At-risk mental state (ARMS) subjects had significantly lower levels of glutamate than control subjects in the thalamus (p < .05) but higher glutamine in the anterior cingulate (p < .05). Within the ARMS group, the level of thalamic glutamate was directly correlated with gray matter volume in the medial temporal cortex and insula (p < .01).Conclusions This study provides the first evidence that brain glutamate function is perturbed in people with prodromal signs of schizophrenia and that glutamatergic dysfunction is associated with a reduction in gray matter volume in brain regions thought to be critical to the pathogenesis of the disorder. These findings support the hypothesis that drugs affecting the glutamate system may be of benefit in the early stages of psychotic illness.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2009.05.006

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences
Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007) · Behavior Research Methods · doi:10.3758/bf03193146 · Cited by 65,971
A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Estimation of metabolite concentrations from localized in vivo proton NMR spectra
Provencher, S. W. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910300604 · Cited by 3,659
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison
Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., John Suckling, A., Phillips, L., Yung, A. R., Bullmore, E. T., Brewer, W. J., Soulsby, B., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12323-9 · Cited by 1,309
Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group
Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S. M., McFarlane, C. A., Hallgren, M., & McGorry, P. D. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00167-6 · Cited by 1,136
Global, voxel, and cluster tests, by theory and permutation, for a difference between two groups of structural MR images of the brain
Bullmore, E. T., Suckling, J., Overmeyer, S., Rabe-Hesketh, S., Taylor, E., & Brammer, M. J. (1999) · IEEE Transactions on Medical Imaging · doi:10.1109/42.750253 · Cited by 1,088

Show all 45 references

Sorted by citations

The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Molecular Targets of Cannabidiol in Neurological Disorders
Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 602
Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
Marsman, A., van den Heuvel, M. P., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr069 · Cited by 457
Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function
Demjaha, A., Egerton, A., Murray, R. M., Kapur, S., Howes, O. D., Stone, J. M., & McGuire, P. K. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.06.011 · Cited by 347
Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis.
Fusar-Poli, P., Borgwardt, S., Crescini, A., Deste, G., Kempton, M., Lawrie, S., Guire, P. M., & Sacchetti, E. (2011) · Neuroscience and Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.12.005 · Cited by 357
Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology
Stone, J. M., Dietrich, C., Edden, R., Mehta, M. A., De Simoni, S., Reed, L. J., Krystal, J. H., Nutt, D., & Barker, G. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.171 · Cited by 295
Prediction of Psychosis by Mismatch Negativity
Bodatsch, M., Ruhrmann, S., Wagner, M., Müller, R., Schultze‐Lutter, F., Frommann, I., Brinkmeyer, J., Gäebel, W., Maier, W., Klosterkötter, J., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.057 · Cited by 284
Presynaptic Striatal Dopamine Dysfunction in People at Ultra-high Risk for Psychosis: Findings in a Second Cohort
Egerton, A., Chaddock, C. A., Winton-Brown, T. T., Bloomfield, M. A. P., Bhattacharyya, S., Allen, P., McGuire, P. K., & Howes, O. D. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.017 · Cited by 253
Dopaminergic basis of salience dysregulation in psychosis
Winton-Brown, T. T., Fusar-Poli, P., Ungless, M. A., & Howes, O. D. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.11.003 · Cited by 231
Neuroanatomical Abnormalities That Predate the Onset of Psychosis
Mechelli, A., Riecher‐Rössler, A., Meisenzahl, E. M., Tognin, S., Wood, S. J., Borgwardt, S., Koutsouleris, N., Yung, A. R., Stone, J. M., Phillips, L., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.42 · Cited by 241
Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis
de la Fuente‐Sandoval, C., León-Ortíz, P., Favila, R., Stephano, S., Mamo, D. C., Ramírez‐Bermúdez, J., & Graff‐Guerrero, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.65 · Cited by 235
How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis
Cannon, T. D. (2015) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2015.09.009 · Cited by 237
Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive
Mouchlianitis, E. D., Bloomfield, M., Law, V., Beck, K., Selvaraj, S., Rasquinha, N., Waldman, A. D., Turkheimer, F., Egerton, A., Stone, J. M., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv151 · Cited by 226
The neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Duration Mismatch Negativity and P3a in First-Episode Psychosis and Individuals at Ultra-High Risk of Psychosis
Atkinson, R. J., Michie, P. T., & Schall, U. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.08.023 · Cited by 204
The role of the thalamus in schizophrenia from a neuroimaging perspective
Pergola, G., Selvaggi, P., Trizio, S., Bertolino, A., & Blasi, G. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.013 · Cited by 203
Outreach and support in South London (OASIS), 2001–2011: Ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis
Fusar‐Poli, P., Byrne, M., Badger, S., Valmaggia, L., & McGuire, P. K. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2012.08.002 · Cited by 197
Research in people with psychosis risk syndrome: a review of the current evidence and future directions
Correll, C. U., Hauser, M., Auther, A. M., & Cornblatt, B. A. (2010) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2010.02235.x · Cited by 204
Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change
Anticevic, A., Hu, X., Xiao, Y., Hu, J., Li, F., Bi, F., Cole, M. W., Savic, A., Yang, G. J., Repovs, G., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2310-14.2015 · Cited by 178
Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia
Kinon, B. J., Millen, B. A., Zhang, L., & McKinzie, D. L. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.016 · Cited by 169
Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia
Egerton, A., Brugger, S. P., Raffin, M., Barker, G. J., Lythgoe, D. J., McGuire, P. K., & Stone, J. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.113 · Cited by 168
Translating the MAM model of psychosis to humans
Modinos, G., Allen, P., Grace, A. A., & McGuire, P. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.005 · Cited by 165
“The notion that increased glutamate levels might lead to reduction in grey matter volume is consistent with data from neuroimaging studies that have combined MRS and MRI in first-episode patients and individuals at UHR [61, 96].”
BackgroundResultInfluentialSelf-citation
Altered Striatal Functional Connectivity in Subjects With an At-Risk Mental State for Psychosis
Dandash, O., Fornito, A., Lee, J., Keefe, R. S. E., Chee, M. W. L., Adcock, R. A., Pantelis, C., Wood, S. J., & Harrison, B. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt093 · Cited by 165
Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality
Lieberman, J. A., Small, S. A., & Girgis, R. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19080865 · Cited by 165
Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Javitt, D. C., Lieberman, J. A., Abi‐Dargham, A., & Girgis, R. R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.12.013 · Cited by 158
Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies
Nakahara, T., Tsugawa, S., Noda, Y., Ueno, F., Honda, S., Kinjo, M., Segawa, H., Hondo, N., Mori, Y., Watanabe, H., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01297-6 · Cited by 171
GABA and glutamate in schizophrenia: A 7 T 1H-MRS study
Marsman, A., Mandl, R. C. W., Klomp, D. W. J., Bohlken, M. M., Boer, V. O., Андрейченко, А. Е., Cahn, W., Kahn, R. S., Luijten, P. R., & Pol, H. E. H. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.10.005 · Cited by 159
Reduced mismatch negativity predates the onset of psychosis
Shaikh, M., Valmaggia, L., Broome, M. R., Dutt, A., Lappin, J., Day, F., Woolley, J., Tabraham, P., Walshe, M., Johns, L., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.09.022 · Cited by 150
Is there an association between peripheral immune markers and structural/functional neuroimaging findings?
Frodl, T., & Amico, F. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.013 · Cited by 150
Glutamate-mediated excitotoxicity in schizophrenia: A review
Plitman, E., Nakajima, S., de la Fuente‐Sandoval, C., Gerretsen, P., Chakravarty, M. M., Kobylianskii, J., Chung, J. K., Caravaggio, F., Iwata, Y., Remington, G. J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.015 · Cited by 150
Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis
Mondelli, V., Pariante, C. M., Navari, S., Aas, M., D'Albenzio, A., Di Forti, M., Handley, R., Hepgul, N., Marques, T. R., Taylor, H., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.021 · Cited by 144
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level
Merritt, K., McGuire, P. K., Egerton, A., 1H-MRS in Schizophrenia Investigators, Aleman, A., Block, W., Bloemen, O., Borgan, F., Bustillo, J., Capizzano, A. A., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0380 · Cited by 142
Thalamic Pathology in Schizophrenia
Cronenwett, W. J., & Csernansky, J. G. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_55 · Cited by 140
Reduced Cortical Thickness as an Outcome of Differential Sensitivity to Environmental Risks in Schizophrenia
Habets, P., Marcelis, M. C., Gronenschild, E. H. B. M., Drukker, M., & van Os, J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.010 · Cited by 142
Longitudinal MRI study of cortical thickness, perfusion, and metabolite levels in major depressive disorder
Järnum, H., Eskildsen, S. F., Steffensen, E. G., Lundbye‐Christensen, S., Simonsen, C. W., Thomsen, I. S., Fründ, T., Théberge, J., & Larsson, E. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01766.x · Cited by 142
Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.
Stone, J., Howes, O., Egerton, A., Kambeitz, J., Allen, P., Lythgoe, D., O'Gorman, R., McLean, M., Barker, G., & McGuire, P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.034 · Cited by 151
Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia—A Systematic Review and Meta-Analysis
Brugger, S., Davis, J. M., Leucht, S., & Stone, J. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.004 · Cited by 131
Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study
Iwata, Y., Nakajima, S., Plitman, E., Caravaggio, F., Kim, J., Shah, P., Mar, W., Chavez, S., Luca, V. D., Mimura, M., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.009 · Cited by 121
Thinking Glutamatergically: Changing Concepts of Schizophrenia Based Upon Changing Neurochemical Models
Kantrowitz, J. T., & Javitt, D. C. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.3.6 · Cited by 120
Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.
Fusar-Poli, P., Stone, J., Broome, M., Valli, I., Mechelli, A., McLean, M. A., Lythgoe, D., O'Gorman, R. L., Barker, G. J., & McGuire, P. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.46 · Cited by 114
Early and broadly defined psychosis risk mental states
Keshavan, M. S., DeLisi, L. E., & Seidman, L. J. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.006 · Cited by 111
Hippocampal pathology in individuals at ultra-high risk for psychosis: A multi-modal magnetic resonance study
Wood, S. J., Kennedy, D., Phillips, L., Seal, M. L., Yücel, M., Nelson, B., Yung, A. R., Jackson, G. D., McGorry, P. D., Velakoulis, D., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.012 · Cited by 114
Lower regional grey matter in alcohol use disorders: evidence from a voxel-based meta-analysis
Li, L., Yu, H., Liu, Y., Meng, Y., Li, X., Zhang, C., Liang, S., Li, M., Guo, W., Wang, Q., et al. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03244-9 · Cited by 110
Mismatch Negativity and Cognitive Performance for the Prediction of Psychosis in Subjects with At-Risk Mental State
Higuchi, Y., Sumiyoshi, T., Seo, T., Miyanishi, T., Kawasaki, Y., & Suzuki, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054080 · Cited by 110
7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia
Reid, M. A., Salibi, N., White, D. M., Gawne, T. J., Denney, T. S., & Lahti, A. C. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx190 · Cited by 106
Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia
Aoyama, N., Théberge, J., Drost, D. J., Manchanda, R., Northcott, S., Neufeld, R. W. J., Menon, R. S., Rajakumar, N., Pavlosky, W. F., Densmore, M., et al. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.079608 · Cited by 105
Core, social and moral disgust are bounded: A review on behavioral and neural bases of repugnance in clinical disorders
Vicario, C. M., Rafal, R. D., Martino, D., & Avenanti, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.008 · Cited by 109
Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.
Natsubori, T., Inoue, H., Abe, O., Takano, Y., Iwashiro, N., Aoki, Y., Koike, S., Yahata, N., Katsura, M., Gonoi, W., et al. (2014) · Schizophrenia bulletin · doi:10.1093/schbul/sbt124 · Cited by 110
Modeling a model: Mouse genetics, 22q11.2 Deletion Syndrome, and disorders of cortical circuit development
Meechan, D. W., Maynard, T. M., Tucker, E. S., Fernandez, A., Karpinski, B. A., Rothblat, L. A., & LaMantia, A. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.004 · Cited by 105
Structural and functional imaging markers for susceptibility to psychosis
Andreou, C., & Borgwardt, S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0679-7 · Cited by 99
Modulatory effects of cannabinoids on brain neurotransmission
Cohen, K., Weizman, A., & Weinstein, A. M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14407 · Cited by 98
Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum
Roalf, D. R., Nanga, R. P. R., Rupert, P. E., Hariharan, H., Quarmley, M., Calkins, M. E., Dress, E. M., Prabhakaran, K., Elliott, M. A., Moberg, P. J., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.258 · Cited by 92
Prefrontal GABA and glutathione imbalance in posttraumatic stress disorder: Preliminary findings
Michels, L., Schulte-Vels, T., Schick, M., Tuura, R., Zeffiro, T. A., Hasler, G., & Mueller‐Pfeiffer, C. (2014) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2014.09.007 · Cited by 88
Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study.
de la Fuente-Sandoval, C., León-Ortíz, P., Azcárraga, M., Favila, R., Stephano, S., & Graff-Guerrero, A. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000314 · Cited by 88
Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy
de la Fuente‐Sandoval, C., Reyes-Madrigal, F., Mao, X., León-Ortíz, P., Rodríguez-Mayoral, O., Solís‐Vivanco, R., Favila, R., Graff‐Guerrero, A., & Shungu, D. C. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv105 · Cited by 89
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis
Egerton, A., Stone, J., Chaddock, C. A., Barker, G., Bonoldi, I., Howard, R. M., Merritt, K., Allen, P., Howes, O., Murray, R., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.143 · Cited by 94
Mismatch negativity (MMN) deficiency: A break-through biomarker in predicting psychosis onset
Näätänen, R., Shiga, T., Asano, S., & Yabe, H. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2014.12.012 · Cited by 82
Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal 1H-MRS Studies
Egerton, A., Bhachu, A., Merritt, K., McQueen, G., Szulc, A., & McGuire, P. K. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00066 · Cited by 84
7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings
Thakkar, K. N., Rösler, L., Wijnen, J. P., Boer, V. O., Klomp, D. W. J., Cahn, W., Kahn, R. S., & Neggers, S. F. W. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.04.007 · Cited by 82
Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia
Bustillo, J., Chen, H., Jones, T., Lemke, N. T., Abbott, C., Qualls, C., Cañive, J. M., & Gasparovic, C. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3939 · Cited by 82
In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia
Wijtenburg, S. A., Yang, S., Fischer, B. A., & Rowland, L. M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.007 · Cited by 83
Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis
Bossong, M. G., Antoniades, M., Azis, M., Samson, C., Quinn, B., Bonoldi, I., Modinos, G., Perez, J., Howes, O. D., Stone, J. M., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3252 · Cited by 81
Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia
Stan, A. D., Ghose, S., Zhao, C., Hulsey, K., Mihalakos, P., Yanagi, M., Morris, S., Bartko, J. J., Choi, C., & Tamminga, C. A. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.54 · Cited by 79
Dysplasticity, metaplasticity, and schizophrenia: Implications for risk, illness, and novel interventions
Keshavan, M. S., Mehta, U. M., Padmanabhan, J. L., & Shah, J. L. (2015) · Development and Psychopathology · doi:10.1017/s095457941500019x · Cited by 79
Mapping prodromal psychosis: A critical review of neuroimaging studies
Fusar‐Poli, P., McGuire, P. K., & Borgwardt, S. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.006 · Cited by 75
Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
Colizzi, M., Weltens, N., McGuire, P. K., Lythgoe, D. J., Williams, S., Oudenhove, L. V., & Bhattacharyya, S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0374-8 · Cited by 74
Auditory event-related potential of subjects with suspected pre-psychotic state and first‐episode psychosis
Hsieh, M. H., Shan, J., Huang, W., Cheng, W.-C., Chiu, M., Jaw, F., Hwu, H., & Liu, C. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.021 · Cited by 72
Sleep dysfunction prior to the onset of schizophrenia: A review and neurodevelopmental diathesis–stress conceptualization.
Lunsford‐Avery, J. R., & Mittal, V. A. (2013) · Clinical Psychology Science and Practice · doi:10.1111/cpsp.12041 · Cited by 80
Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation
Salavati, B., Rajji, T. K., Price, R., Sun, Y., Graff‐Guerrero, A., & Daskalakis, Z. J. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu132 · Cited by 71
A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk
Sydnor, V. J., & Roalf, D. R. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.06.028 · Cited by 68
Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies
Schwerk, A. M. K., Alves, F. D. S., Pouwels, P. J. W., & van Amelsvoort, T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12398 · Cited by 68
Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy
Tandon, N., Bolo, N. R., Sanghavi, K., Mathew, I. T., Francis, A., Stanley, J. A., & Keshavan, M. S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.024 · Cited by 68
Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation.
Allen, P., Chaddock, C. A., Egerton, A., Howes, O., Barker, G., Bonoldi, I., Fusar-Poli, P., Murray, R., & McGuire, P. (2015) · Schizophrenia bulletin · doi:10.1093/schbul/sbu115 · Cited by 74
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?
Stone, J. M. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311400779 · Cited by 60
In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study
Chiu, P. W., Lui, S. S. Y., Hung, K. S. Y., Chan, R. C. K., Chan, Q., Sham, P. C., Cheung, E. F. C., & Mak, H. K. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.021 · Cited by 60
Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis.
Valli, I., Stone, J., Mechelli, A., Bhattacharyya, S., Raffin, M., Allen, P., Fusar-Poli, P., Lythgoe, D., O'Gorman, R., Seal, M., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.033 · Cited by 72
Using neuroimaging to help predict the onset of psychosis
Gifford, G., Crossley, N. A., Fusar‐Poli, P., Schnack, H. G., Kahn, R. S., Koutsouleris, N., Cannon, T. D., & McGuire, P. K. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.03.075 · Cited by 62
Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801
Roenker, N. L., Gudelsky, G. A., Ahlbrand, R., Bronson, S. L., Kern, J. R., Waterman, H., & Richtand, N. M. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.06.011 · Cited by 59
Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample
Bustillo, J., Jones, T., Chen, H., Lemke, N. T., Abbott, C., Qualls, C., Stromberg, S. F., Cañive, J. M., & Gasparovic, C. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw122 · Cited by 58
Structural Brain Alterations in Individuals at Ultra-high Risk for Psychosis: A Review of Magnetic Resonance Imaging Studies and Future Directions
Jung, W. H., Jang, J. H., Byun, M. S., An, S. K., & Kwon, J. S. (2010) · Journal of Korean Medical Science · doi:10.3346/jkms.2010.25.12.1700 · Cited by 60
Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study: Table 1.
Klauser, P., Zhou, J. H., Lim, J. K. W., Poh, J. S., Zheng, H., Tng, H. Y., Krishnan, R. K. R., Lee, J., Keefe, R. S. E., Adcock, R. A., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv012 · Cited by 54
Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia
Jelen, L. A., King, S., Mullins, P. G., & Stone, J. M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117747579 · Cited by 54
Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis
Trzesniak, C. M. F., Kempton, M. J., Busatto, G. F., de Oliveira, I. R., Almeida, A. G.-D., Kambeitz, J. P., Ferrari, M. C. F., Filho, A. S., Chagas, M. H. N., Zuardi, A. W., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.024 · Cited by 54
Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis
Whitehurst, T., Osugo, M., Townsend, L., Shatalina, E., Vava, R., Onwordi, E. C., & Howes, O. D. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.10.001 · Cited by 56
Proton Magnetic Resonance Spectroscopy in 22q11 Deletion Syndrome
Alves, F. D. S., Boot, E., Schmitz, N., Nederveen, A. J., Vorstman, J. A. S., Lavini, C., Pouwels, P. J. W., de Haan, L., LINSZEN, D. H., & van Amelsvoort, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021685 · Cited by 50
Hippocampal Shape Abnormalities Predict Symptom Progression in Neuroleptic-Free Youth at Ultrahigh Risk for Psychosis
Dean, D. J., Orr, J. M., Bernard, J. A., Gupta, T., Pelletier‐Baldelli, A., Carol, E. E., & Mittal, V. A. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv086 · Cited by 55
Guided exploration of genomic risk for gray matter abnormalities in schizophrenia using parallel independent component analysis with reference
Chen, J., Calhoun, V. D., Pearlson, G. D., Perrone‐Bizzozero, N. I., Jing Sui （Beijing Normal University）， my correct affiliation is beijing normal university, N. Q. U. O. S. A. T., Turner, J. A., Bustillo, J., Ehrlich, S., Sponheim, S. R., Cañive, J. M., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.073 · Cited by 51
Multimodal functional and structural imaging investigations in psychosis research
Schultz, C. C., Fusar‐Poli, P., Wagner, G., Koch, K., Schachtzabel, C., Gruber, O., Sauer, H., & Schlösser, R. G. M. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0360-5 · Cited by 52
The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
Egerton, A., & Stone, J. M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784961 · Cited by 51
Cerebellar Morphology and Procedural Learning Impairment in Neuroleptic-Naive Youth at Ultrahigh Risk of Psychosis
Dean, D. J., Bernard, J. A., Orr, J. M., Pelletier‐Baldelli, A., Gupta, T., Carol, E. E., & Mittal, V. A. (2013) · Clinical Psychological Science · doi:10.1177/2167702613500039 · Cited by 48
Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of 1H-MRS studies.
Wenneberg, C., Glenthøj, B., Hjorthøj, C., Zingenberg, F. J. B., Glenthøj, L., Rostrup, E., Broberg, B., & Nordentoft, M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.10.050 · Cited by 51
Gray Matter Volumetric Abnormalities Associated with the Onset of Psychosis
Jung, W. H., Borgwardt, S., Fusar‐Poli, P., & Kwon, J. S. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00101 · Cited by 43
Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis
Shakory, S., Watts, J. J., Hafizi, S., Silva, T. M. S., Khan, S. M., Michael Kiang, A., Bagby, R. M., Chavez, S., & Mizrahi, R. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0163-0 · Cited by 44
Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity
Shah, P., Plitman, E., Iwata, Y., Kim, J., Nakajima, S., Chan, N. K., Brown, E. E., Caravaggio, F., Torres, E., Hahn, M., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.02.032 · Cited by 44
Sense of agency is altered in patients with a putative psychotic prodrome
Hauser, M., Moore, J. W., de Millas, W., Gallinat, J., Heinz, A., Haggard, P., & Voss, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.10.031 · Cited by 49
Metabolite Alterations in Adults With Schizophrenia, First Degree Relatives, and Healthy Controls: A Multi-Region 7T MRS Study
Wijtenburg, S. A., Wang, M., Korenic, S. A., Chen, S., Barker, P. B., & Rowland, L. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.656459 · Cited by 40
Sleep Spindles Are Related to Schizotypal Personality Traits and Thalamic Glutamine/Glutamate in Healthy Subjects
Lustenberger, C., Tuura, R., Pugin, F., Tüshaus, L., Wehrle, F. M., Achermann, P., & Huber, R. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu109 · Cited by 40

Authors: Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K.
Affiliations: University of London (GB)
UCL Queen Square Institute of Neurology (GB)
Corresponding author: Stone, James M.
ORCID: Stone, James M.
Day, Fern
Valli, Isabel
McLean, Mary A.
Lythgoe, David J.
Barker, Gareth J.
McGuire, Philip K.
Venue: Biological Psychiatry
Publisher: Elsevier BV
Published: 2009-09
Volume: 66
Issue: 6
Pages: 533-539
ISSN: 0006-3223 (ISSN-L)
DOI: 10.1016/j.biopsych.2009.05.006
OpenAlex: W1994737820
Cited by: 231
References: 45
Citations by year: 2026: 4 · 2025: 3 · 2024: 4 · 2023: 7 · 2022: 3 · 2021: 13 · 2020: 16 · 2019: 17 · 2018: 11 · 2017: 11 · 2016: 10 · 2015: 20 · 2014: 21 · 2013: 20 · 2012: 21
FWCI: 14.60
Type: journal article
Language: en
Open access: green
kclpure.kcl.ac.uk
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biological Psychiatry (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: glutamate dysfunction, glutamatergic neurotransmission, schizophrenia, clinical high risk for psychosis, prodromal psychosis, gray matter volume, glutamine, thalamus, anterior cingulate cortex, hippocampus, insula, neurotoxicity, 1H NMR
MeSH terms: Adult, Mental Disorders, Brain Mapping, Female, Glutamine, Humans, Magnetic Resonance Imaging, Male, Magnetic Resonance Spectroscopy, Protons, Psychiatric Status Rating Scales, Risk, Temporal Lobe, Thalamus, Glutamic Acid, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks